Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 1 天前评分70
正文 · 原文
FINER demonstrates ipatasertib + fulvestrant improves PFS (but not OS) for both ITT and AKT pathway altered cohorts with notable AEs
#ESMO26 @OncoAlert
50 浏览 · 3 赞 · 3 转发 · 1 回复
会议摘要
LBA14按 Proffered paper 2: Breast cancer, early and advanced stage 对上
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/
https://esmocongress.esmo.org帖内回复
- Ziad Storyteller@AIZiadSaliba
@DrSGraff @OncoAlert I think the signal is in the AKT pathway-altered cohort (HR 0.55), and the cfDNA stratification is the methodologically interesting part. Median PFS ~5.5 months with 92.7% diarrhea and 16.9% grade 3 is a hard trade post-CDK4/6i #ESMO26
来源：Stephanie Graff, MD, FACP, FASCO · x.com